Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

442 Study Matches

Characterization and Exploration of Cognitive Assistants in the Space of Knowledge and Social Demands

The objective of this study is to investigate the effects of artificial intelligence on ideation in groups (specifically the process of brainstorming). Facilitation and facilitator/participant perceptions will also be analyzed. This study collects qualitative data through surveys, interviews, and audio/video recording.
Torsten Maier at torstennamaier@psu.edu or 812-781-0014
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Individuals must be 18 years of age or older
Individuals must be an undergraduate OR graduate student at Penn State
Exclusion Criteria:
Individuals under the age of 18
Individuals who are not an undergraduate OR graduate student at Penn State
Education, Language & Linguistics
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Using Exercise to Relieve Arthralgia (Joint Pain) and Improve AI Adherence in Older Survivors (REJOIN): A Pilot Study

Briefly, the purpose of this study is to use a self-management approach (combining education and exercise) to help older breast cancer survivors manage joint pain, a common side effect of aromatase inhibitors (AIs), a medication used to reduce hormones that might increase risk of recurrence and mortality following primary cancer treatment. We believe that reducing joint pain might help survivors take their medication longer and thus improve survival outcomes, compared to standard care.
Shirley Bluethmann at szb332@psu.edu
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03955627
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 65 and older
Female
Breast Cancer Survivor
Preparing to Start AI medication
ER+ diagnosis
Exclusion Criteria:
Already taking AI medication (greater than 2 weeks)
Gross Cognitive Impairment
Recent Joint Surgery
Cardiac event/Stroke within last 6 months
Not willing to come to HMC for Exercise Sessions
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Muscular Dystrophy Association Neuromuscular Observational Research (MOVR) Data Hub Protocol

The Muscular Dystrophy Association (MDA) wants to collect information about individuals with neuromuscular disease to better understand the disease progression and ultimately improve the medical care, quality of life, and survival of those with neuromuscular disease. To collect this information, MDA has created a data registry called the Neuromuscular Observational Research Data Hub (referred to as the “MOVR Data Hub”). The MOVR Data Hub is a kind of database — a way of collecting and storing information.
All
All
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosed with a neuromuscular condition
Exclusion Criteria:
Unwilling to provide informed consent
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Evaluating perceptions of teledermatology for people with Hidradenitis Suppurativa.

We would like to assess patient perceptions regarding willingness to use teledermatology services for people with hidradenitis suppurativa (HS).
Melissa Butt at mbutt1@pennstatehealth.psu.edu or 717-531-6117
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years of age or older
Diagnosed with Hidradenitis Suppurativa
Can read and write in English
Access to the internet
Exclusion Criteria:
Less than 18 years old
No diagnosis of HS
No access to internet
Skin Conditions
  Email this study information to me
  Contact the study team

Understanding the Well-being of Advanced Counseling Students of Color

The primary objective of this study is to increase our understanding of the ways in which perceived discrimination, coping strategies, competence, stress, social support, and self-efficacy in counselor education programs relate to overall well-being for advanced counseling students of color.
Kyesha Isadore at kmi5@psu.edu or 337-326-3788
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Currently enrolled as a master’s or doctoral student in a counseling education program
18 years of age or older
Capable of providing informed consent without the assistance of a legal guardian
Identify as a racial or ethnic minority
Able to understand written and spoken English at the time of the survey
Exclusion Criteria:
Adults unable to consent
Individuals who are not yet adults (infants, children, teenagers)
Education, Mental & Behavioral Health
  Email this study information to me
  Contact the study team

The Effect of Resistance Exercise on Craving and Cannabis Use in Individuals with Cannabis Use Disorder

Cannabis is the most widely used illicit drug and rates of hazardous use, and cannabis use disorders (CUDs), have continued to rise in recent years. Increased exposure produces higher risk for detrimental psychological and behavioral effects of cannabis use. Given this increased prevalence of problematic cannabis use, identifying effective behavioral strategies for individuals experiencing problems with addiction would offer significant benefits. Exercise, particularly resistance exercise, is a behavioral intervention with considerable potential as an adjunctive treatment for CUD. No prior study has investigated the effects of an acute bout of resistance exercise on cannabis craving and consumption, nor has prior research identified what psychobiological mechanisms may underlie these exercise potentiated effects. The aims of this proposal seek to address these issues by implementing an acute resistance exercise protocol in men and women who have severe cannabis use disorder. This proposal will examine the acute effects of resistance exercise on craving, mood, anxiety, and markers of reward and stress regulation. In addition, this proposal will examine the trajectory of these effects in the subsequent days.
Gwendolyn Thomas at gat112@psu.edu or 814-863-3172
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT03867786
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Cannabis Use
Between 18-30 years old
Recreationally trained
Able to read write English and complete study evaluations
Provide negative toxicology screenings for nicotine or alcohol at intake
Exclusion Criteria:
Women who are pregnant or lactating
Known endocrine disorder
Blood clotting disorders
Any psychiatric disorder or current psychiatric symptoms
Inability to give informed consent
Addiction & Substance Abuse
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Examining contextual factors associated with food-related reward and eating restraint

Rates of obesity have risen sharply throughout the world over the past several decades. The increase in the availability of highly palatable, high-calorie foods may be one factor that has contributed to this trend. That is, the availability of such foods may lead to their over-consumption and corresponding weight gain. Currently, relatively little is known about how the availability of foods, per se, affects things such as the motivation to eat and the ability to resist doing so. The current study is designed to help address this knowledge gap by examining the effects of food availability in people with high levels of dietary restraint. Dietary restraint, which refers to the intention to restrict food intake deliberately in order to prevent weight gain or to promote weight, is linked to problematic patterns of eating. This project uses laboratory tasks and brain imaging to study the effects of food availability on various outcomes, including food choices, food craving, and responses in brain areas linked to motivation.
Josie Huang at suh438@psu.edu or 814-867-2333
Female
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participants must be between the ages of 18 and 45.
Participants must be right handed.
Participants must be fluent English speakers.
Participants must have a body mass index (BMI) >= 25.
Participants must have experienced food eating/weight issues.
Exclusion Criteria:
If participants are currently engaging in active dieting behaviors (e.g., a weight loss program) or they are taking medications that could alter appetite or body weight.
If participant have a lifetime history of diagnosed eating disorders, diabetes, hyperglycemia, high levels of triglycerides, or high cholesterol or other related medical conditions.
If participants have any known risk from exposure to high-field strength magnetic fields (e.g., pace makers), any irremovable metallic foreign objects in their body (e.g., braces), or a questionable history of metallic fragments.
If participants report that they are vegetarian/vegan.
If participants are not willing to refrain from using alcohol for 24 hours or from using nicotine products/recreational drugs for 3 weeks, or unwilling to fast from food for 5 hours prior to two of three lab visits.
Food & Nutrition, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Vernacular Feature Comprehension and Perception in Persons with Aphasia

This study investigates whether persons with aphasia understand and process sentences with vernacular features in a manner similar to more typical populations. Participants will rate sentences on their naturalness and on whether they make sense, and they will also read sentences while we track their eye movements.
Frances Blanchette at fkb1@psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
1. Diagnosis of aphasia
2. Sustained stroke more than 6 months prior to consent
3. Native speakers of English
4. Completed at least a high school education
5. Normal or corrected-to-normal vision and hearing
Exclusion Criteria:
1. History of degenerative neurological disorders (e.g., Alzheimer’s disease), acquired neurological disorders other than aphasia from stroke (e.g., traumatic brain injury), developmental neurological disorders (e.g., autism), or psychiatric disorders
2. An active medical condition that could compromise participation (e.g., cancer undergoing acute treatment)
3. Taking medications that are known to exert significant effects on cognitive processes
4. Do not meet the above inclusionary criteria
Language & Linguistics
  Email this study information to me
  Contact the study team
  Show all 2 locations

Study Locations

Hide all locations
Location
Hershey, PA
State College, PA

Phones, Apps, and Sedentary Time

This study is examining the relationship between physical activity and smartphone use. Over a 10-day period, activity monitoring, questionnaires, and Apple Screentime software are used to track behaviors.
Abigail Faust at avf5371@psu.edu or 814-865-7935
All
All
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between 13 to 29 years of age
Able to read, speak, and understand English
Must own or be the sole user of an iPhone smartphone
The iPhone owned or used by the participant must be version 5S or later
Participant must be residing in the state of Pennsylvania
Exclusion Criteria:
Currently limiting smartphone use
Children's Health, Mental & Behavioral Health
  Email this study information to me
  Contact the study team

Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age

This study is to see if venetoclax in combination with bendamustine and rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to examine the side effects, good and bad, associated with this combination .
Jennifer Petrask at jpetrask@pennstatehealth.psu.edu or 717-531-8678
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03834688
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must have histologically confirmed (biopsy-proven) diagnosis of mantle cell lymphoma (MCL)
Must have measurable or evaluable disease as defined as a lymph node measuring >1.5 cm in any dimension or splenomegaly with spleen >15 cm in craniocaudal dimension
ECOG performance status of 0-2
Adequate organ function as measured by the criteria
Total Bilirubin ≤ 1.5x upper limit of normal (ULN) or ≤ 3x ULN with documented Gilbert’s syndrome
Exclusion Criteria:
Should not have known evidence of central nervous system (CNS) lymphoma
Should not have prior chemotherapy, radiotherapy or immunotherapy for lymphoma
Must not have received a prior allogeneic stem cell transplant or solid organ transplant (except for cornea) for any indication
Must have no active, uncontrolled infections
Must not have active hepatitis B or be chronic carriers of hepatitis B.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Effects of heating on exercise pressor reflex in peripheral artery disease: Exercise Ability

To determine if the sympathetic and blood pressure (BP) responses to exercise will be attenuated during and after heat exposure in patients with peripheral artery disease (PAD).
Cheryl Blaha at cblaha@pennstatehealth.psu.edu or 717-531-1605
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
healthy females and males
all minorities and ethnicies included
free of acute or chronic medical conditions
over 21 years old
Exclusion Criteria:
Females who are pregnant or lactating
under 21 years old
Decisional impairment
Heart & Vascular
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) (PSCI# 19-079) (S1803)

This study is being done to answer the following questions: 1. Will adding the drug daratumumab/rHuPH20 to the usual maintenance treatment with lenalidomide after stem cell transplant help multiple myeloma patients survive longer? 2. For patients who have no evidence of multiple myeloma in their bone marrow (patients who do not have “minimum residual disease” [MRD-negative]), should maintenance therapy be stopped after 2 years? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your multiple myeloma. The usual approach is defined as care most people get for multiple myeloma.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04071457
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patients must have had a confirmed diagnosis of symptomatic multiple myeloma (See Section 4.1) that required systemic induction therapy prior to autologous stem cell transplantation (ASCT).
Patients with disease measurable by serum light chain assay alone are eligible (defined as ≥ 100 mg/L on involved light chain).
Patients must be ≥ 18 and ≤ 75 years of age at time of registration to Step 1.
Patients must have history and physical exam within 28 days prior to registration.
Patients must have Zubrod Performance Status ≤ 2.
Exclusion Criteria:
Patients with smoldering myeloma are not eligible
Patients must not have any organ involvement by amyloidosis or evidence of amyloidosis related organ dysfunction.
Patients must not have progressive disease at any time prior to registration.
Patients must not be refractory or intolerant to either lenalidomide or daratumumab/rHuPH20.
Patients must not have moderate or severe persistent asthma within the past 2 years and must not have currently uncontrolled asthma of any classification.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Robots that Learn Games by Asking People Questions

The study goal is to develop robots that can learn simple games by interviewing humans. The robot interview strategies are represented as Markov Decision Process policies, and are developed offline through robot interactions with simulated interviewees. The investigator can set the simulated interviewee to respond to the robot's queries with different amounts of information. The games include board games like Connect 4, Quarto, and Checkers. The communication between the robot and simulated interviewee is in a formal language like first order logic. After a simulated dialogue, the robot will have more or less knowledge of the game, depending on the conditions of the simulated interviewee. Human subjects will interact with the robots in two ways. First, to test the utility of the new knowledge, human subjects will participate in experiments where they play the game with virtual robots that have learned the game under different conditions. Second, to investigate the kinds of misunderstandings of questions and answers that might arise if the robot could interview a human, we will present subjects with extracts from the formal language dialogues that we have mapped to English in different ways, and ask subjects to imagine how they would express the same meaning in English, or answer questions in different ways, or what sorts of misunderstandings they might imagine in a real dialogue.
Maryam Zare at muz50@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Over 18 years of age
Ability to communicate in written and spoken English
Able to give informed consent
Exclusion Criteria:
Below 18 years of age
Unable to communicate in written and spoken English
Unable to give informed consent
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

A151216-Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (Alchemist)

Purpose of study is to examine lung cancer patients' surgically removed tumors for certain genetic changes and to possibly refer these patients to a treatment study with drugs that may specifically these tumors.
Michelle Eschbach at meschbach@pennstatehealth.psu.edu or 610-378-2336
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02194738
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Surgically resected non-small cell lung cancer
Pathologic stage IIIA, II (IIA or IIB) or large IB (defined as size ≥4 cm).
Tissue available for the required analyses
Exclusion Criteria:
No patients with recurrence of lung cancer after prior resection
No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD1/PD-L1/CTLA-4.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Reading, PA

Site for A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer (NRG-HN005) (PSCI# 20-011)

The purpose of the first part of this study is to compare the usual treatment of a standard-dose radiation given over 6 weeks with cisplatin chemotherapy to a reduced-dose radiation given over either 6 weeks with cisplatin or 5 weeks with the immunotherapy drug, nivolumab. A lower dose of radiation as compared to the usual radiation treatment dose could be as effective in lengthening the time without your cancer getting worse. Nivolumab with reduced-dose radiation may or may not be as effective in lengthening the time without your cancer getting worse. This study will help the study doctors find out if this different approach is the same or worse than the usual approach.
Irina Geier at igeier@pennstatehealth.psu.edu or 717-531-4300
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03952585
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically proven diagnosis of squamous cell carcinoma of the oropharynx
Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations
P16-positive based on local site immunohistochemical tissue staining
Zubrod Performance Status of 0-1 within 14 days prior to registration
Only English, Spanish, or French speaking patients are eligible to participate as these are the only languages for which the mandatory dysphagia-related patient reported instrument (MDADI) is available
Exclusion Criteria:
Clinical stages T0; T4; T1-2, N0; or any N2 (AJCC, 8th ed)
Recurrent disease
Definitive clinical or radiologic evidence of metastatic disease or adenopathy below the clavicles
Cancers considered to be from an oral cavity site or the nasopharynx, hypopharynx, or larynx, even if p16-positive, or histologies of adenosquamous, verrucous, or spindle cell carcinomas
Carcinoma of the neck of unknown primary site origin (T0 is ineligible, even if p16-positive)
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

The Neural Basis of Pattern Learning in Human Adults

This research investigates how the human adult brain exploits patterns and regularities in the environment to learn.
Elisabeth Karuza at ekaruza@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between 18-30 years old
Minimum High School education
Right-handed
Normal or corrected-to-normal vision/hearing
Fluent in English
Exclusion Criteria:
Individuals with a history of neurological injury or disease
Individuals taking medications that affect the brain or blood flow
Individuals greater than 300 lbs
Individuals who are claustrophobic
Individuals with contraindications to MRI scanning such as an implanted device
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Observations of Family Mealtime Routines

The purpose of this study is to gather information about what family mealtimes look like for families with children between the ages of 3 and 8. Families will be asked to video record their family mealtime, in addition to answer some questions and to complete some questionnaires, some about body image and dieting.
Hannah Mudrick at hxm99@psu.edu or 717-948-6404
All
All
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least one adult who is the caregiver of at least one child between age 3 and 8 (e.g., at least one parent-child dyad)
Adults age 18 and older
Children, ages 3-8
Individuals fluent in English
Exclusion Criteria:
Non-family members, as defined individually by each family
Caregivers who are under the age of 18
Individuals who are not fluent in English
Families without at least one child age 3 to 8
Children's Health, Food & Nutrition
  Email this study information to me
  Contact the study team
  Show all 17 locations

Study Locations

Hide all locations
Location
Altoona, PA
Carlisle, PA
DuBois, PA
Erie, PA
Greater Philadelphia Area, PA
Greater Pittsburgh Area, PA
Harrisburg, PA
Hazleton, PA
Hershey, PA
Mont Alto, PA
Reading, PA
Schuylkill Haven, PA
Sharon, PA
State College, PA
Wilkes-Barre/Scranton Area, PA
Williamsport, PA
York, PA

The association between perceived parenting styles, intolerance of uncertainty, and anxiety among young adults

This study aims to understand the association between young adults' perceived parenting, intolerance of uncertainty, and trait anxiety. Participant will be asked to complete a questionnaire that aims to answer the environment and parenting beliefs around which they were brought up, and if they face stressors and anxieties associated with them. This is a correlational study
Aishwarya Sastry at ams9680@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18-34 years old
Geographical location: USA
All genders
All ethnicities
Exclusion Criteria:
Individuals below 18 years
Individuals over 34 years
Individuals residing outside USA
Prevention, Education, Mental & Behavioral Health
  Email this study information to me
  Contact the study team

The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

To evaluate the efficacy of the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer as measured by Overall Survival (OS).
Lea Russell at lrussell@pennstatehealth.psu.edu
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03398655
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Histologically confirmed epithelial ovarian cancer and documented disease.
Patients must have platinum-resistant disease
Patients must have disease that is measurable according to RECIST 1.1 and require chemotherapy treatment.
Adequate hematological functions: ANC ≥ 1000/mm3 PLT ≥ 100,000/mm3 PT and PTT (seconds) < 1.2 X ULN. Patients who are anticoagulated do not need to meet criteria for PT and PTT.
Patients who are known to carry a BRCA mutation may be enrolled only after (following PARP inhibitor treatment failure, or being intolerant of, or ineligible for PARP inhibitor treatment).
Exclusion Criteria:
Non-epithelial tumors (Carcino-sarcomas are excluded)
Ovarian tumors with low malignant potential (i.e. borderline tumors) clear cell carcinomas, grade 1 serous tumors or mucinous tumors.
Patients who had evidence of disease progression during or up to 90 days from the last dose of the first line of platinum based therapy
Previous ovarian cancer treatment with >5 anticancer regimens.
Any prior radiotherapy to the pelvis or whole abdomen.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors

Part 1 (Phase Ib): To determine the safety and ability for subjects to tolerate APG-115 when combined with pembrolizumab, as well as the maximum tolerated dose in subjects with metastatic melanomas or solid tumors. Part 2 (Phase II): To determine the overall response rate of APG-115 when combined with pembrolizumab in the treatment of patients with unresectable or metastatic melanomas.
Irina Geier at igeier@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03611868
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Male or non-pregnant, non-lactating female patients age ≥18 years on day of signing the informed consent
Histologically confirmed, unresectable or metastatic melanoma, and refractory or relapse after PD1 antibody treatment and ineligible for other standard of care therapy
ECOG Performance scale of 0-2
Life expectancy of equal to or greater than 3 months
Adequate bone marrow and organ functionAdequate
Exclusion Criteria:
Any prior systemic MDM2-p53 inhibitor treatment Received chemotherapy within 21 days (42 days for nitrosoureas or mitomycin C) prior to first dose.
Prior loco-regional treatment with intralesional therapy (e.g. talimogene laherparepvec) for unresectable or metastatic melanoma in the last 6 months prior to start of study treatment.
Received hormonal and biologic (<1 half-lives), small molecule targeted therapies or other anti-cancer therapy within 21 days prior to first dose Radiation or surgery within 14 days of study entry, thoracic radiation within 28 days prior to first dose.
Has known active central nervous (CNS) metastases and/or carcinomatous meningitis. Or has neurologic instability per clinical evaluation due to tumor involvement of the CNS.
Requirement for corticosteroid treatment, with the exception of megestrol, local use of steroid: i.e.: topical corticosteroids, inhaled corticosteroids for reactive airway disease, ophthalmic, intraarticular, and intranasal steroids.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Behavior, Voice, and Sex Hormones Study

Hormones are molecules that deliver signals throughout the body. They influence behavior, sleep, hunger, stress, and virtually all other aspects of life. This study seeks to better understand several of these functions, specifically how hormones affect specific aspects of human behavior and psychology, as well as speech production. Following an initial lab visit, subjects will participate in the remainder of the study (~5 weeks) at home via the internet. On a daily basis, they will collect urine samples for hormone analysis, saliva samples for analysis of oral micro-organisms, and will submit voice samples for analysis of speech (e.g. measuring voice pitch and loudness). They will then complete an online survey designed to collect information about their behavior, and attitudes over the previous 24 hours. Subjects receive compensation for their participation.
Kevin Rosenfield at kar61@psu.edu
Female
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between 18 and 30 years of age
Normal menstrual cycles
Available for daily at-home session for approximately 5 weeks
Female/Identifying as a woman
Predominantly or exclusively heterosexual sexual orientation
Exclusion Criteria:
Use of hormonal birth control
Uncorrected severe defects of hearing, speech, or vision
Bisexual or predominantly homosexual sexual orientation
Very heavy smoking or alchohol consumption
On hormonal birth control
Language & Linguistics, Diabetes & Hormones, Women's Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)(KEYNOTE-867)(MK 3475-867)

This Phase 3 study is to compare the Event Free Survival (EFS) of using SBRT in combination with pembrolizumab and compared to SBRT in combination with placebo. To compare Overall Survival (OS) of using SBRT in combination pembrolizumab and compared to SBRT in combination with placebo.
Irina Geier at igeier@pennstatehealth.psu.edu or 717-531-8678
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03924869
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Has an ECOG Performance Status of 0, 1, or 2.
Has previously untreated NSCLC diagnosed by histology or cytology and confirmed as Stage I or IIA NSCLC (AJCC 8th edition) by chest CT and PET scan.
Cannot undergo thoracic surgery due to existing medical illness(es)
A female is eligible to participate if she is not pregnant and not breastfeeding
Is male or female ≥18 years of age
Exclusion Criteria:
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor
Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or breast
Has received a live vaccine within 30 days prior to the first dose of study drug.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

This is a drug study, that will evaluate the potential effectiveness of an investigational drug called pamrevlumab, compared to a placebo, in patients diagnosed with Idiopathic Pulmonary Fibrosis.
Donna Griffiths at dgriffiths@pennstatehealth.psu.edu or 717-531-5519
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03955146
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 40 to 85 years
Diagnosis of Idiopathic Pulmonary Fibrosis
Impaired Pulmonary Function Test Results
Exclusion Criteria:
Diagnosed Obstructive Lung Disease
Nursing or pregnant females
Currently smoking
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Preventing de novo portal vein thrombosis with Antithrombin-III in patients with cirrhosis: A randomized, double-blinded, placebo - controlled trial (PiVoT-AC Trial)

Portal vein thrombosis (PVT) is blockage or narrowing of the portal vein (the blood vessel that brings blood to the liver from the intestines) by a blood clot. It is a common complication in patients with cirrhosis. There is an understanding that patients with cirrhosis are at higher risk for clotting events. This study will examine the use of antithrombin III (a protein found in the body) as a potential drug that may prevent blood clotting in patients with cirrhosis.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04055389
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults age ≥18 or ≤75 years
Cirrhosis diagnosis
Exclusion Criteria:
pregnancy
active Hepatitis C infection
HIV infection
recent major surgery within six weeks
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Student Experience in New Class Modes during Covid-19

This is a survey study that will examine how the new instruction modes during COVID-19 have impacted undergraduate education experience. Participants will be asked to complete a survey to give feedback and comments on their classes. The survey will take 15 - 20 minutes.
Chuhao Wu at cjw6297@psu.edu or 765-772-8073
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or order
An active undergraduate student at University Park campus
Enrolled for as least one class
Can read instruction materials written in English
Exclusion Criteria:
NA
Education
  Email this study information to me
  Contact the study team

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa: Phase 2 Double-Blinded to Open-Label Study, up to 60 weeks long. Oral medication, Males/Females 18-75 years old with Hidradenitis Suppurativa (HS) for at least 3 months Hidradenitis Suppurativa (HS), is a long-lasting, inflammatory skin condition. HS is characterized by lesions that can be found most commonly in the groin, armpits, and buttocks. These lesions are very painful and can drain and cause scarring. The purpose of this study is to find out if the study drug, INCB054707 can help treat HS.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04476043
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
HS diagnosis for at least 3 months
HS lesions in at least 2 different areas
Willing to follow all study guidelines
Exclusion Criteria:
Certain treatments for HS are not allowed; coordinator will discuss specific treatments
Positive test results for HIV, hepatitis B, or hepatitis C
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Personal Narratives by Autistic Adults of Under-Represented Genders

This study seeks to collect and analyze narratives by autistic adults, especially people whose genders are under-represented in the research literature (i.e. female, transgender, and nonbinary people). Some cisgender males can also participate. We plan to describe characteristics of the narratives that might help clinicians more accurately diagnose adults with autism.
Kelly Coburn at klc92@psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosed with an autism spectrum disorder, or scoring above cutoff on a screening measure
Age 18 years or older
Native speaker of American English
Able to participate in an Internet conference with a researcher
No reported hearing loss
Exclusion Criteria:
No autism spectrum diagnosis, and scoring below cutoff on a screening measure
Under 18 years of age
Native speaker of a language other than American English
No access to an Internet connection sufficient for a remote conference
Presence of hearing loss
Mental & Behavioral Health, Language & Linguistics
  Email this study information to me
  Contact the study team

Site for MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) (S1827) (PSCI# 20-086)

The purpose of this study is to compare the effects of using brain MRIs alone versus brain MRIs plus PCI on the lifespan of patients with small cell lung cancer. The use of brain MRIs alone could reduce side effects of receiving PCI. This study is hoping to show that monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) is at least as good as the combination of PCI with MRI scans. There will be about 668 people taking part in this study.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04155034
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient must have a histologically confirmed diagnosis of small-cell lung cancer (SCLC).
Patient must have an MRI of the brain performed within 28 days prior to registration.
Patient must have Zubrod Performance Status of 0-2
Patient must be ≥ 18 years of age.
All adverse events from prior treatment must have resolved to ≤ Grade 2 (CTCAE Version 5.0) prior to randomization.
Exclusion Criteria:
Patient must not have a contraindication to gadolinium contrast administration during MR imaging, such as allergy or insufficient renal function
Patient must not have other metastatic malignancies requiring current active treatment.
Patient must not have any severe active comorbidities
Patient must not have received prior radiotherapy to the brain or whole brain radiotherapy.
Patient must not have a contraindication to MR imaging, such as implanted metal devices or foreign bodies
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Testing feasibility of the BACtrack Skyn device for collecting transdermal alcohol concentrations in free-living humans

The purpose of this voluntary research study is to determine user acceptability of using the BACtrack Skyn wrist-based sensor to track alcohol consumption behaviors in daily life. We are also interested in understanding how people feel about wearing a wrist-based alcohol sensor versus an ankle-mounted alcohol sensor (SCRAM), and their comfort with wearing these sensors, as well as a thigh-mounted physical activity sensor (activPAL), over a 28-day period. By understanding the acceptability of wearing these devices over a 28-day period, researchers will be informed of reasonable alternatives for measuring alcohol use and physical activity in real-world settings. This information will inform future research examining how such health behaviors may interact with each other to affect human health and the risk for diseases like cancer. If your are interested in participating, please follow the link to the screening survey to determine if you are eligible: https://redcap.ctsi.psu.edu/surveys/?s=HMPLJKX7T8 (if the link does not work, please copy and paste it into your browser).
Jimikaye Courtney at jimikaye@psu.edu or 814-856-7935
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
26 to 40 years old
Own an Apple phone
Able to participate in unassisted physical activity
Consume alcohol at least two or more days per week
Reliable internet access
Exclusion Criteria:
Pregnant
History of cancer diagnosis/current cancer diagnosis
At risk for an alcohol use disorder
Addiction & Substance Abuse, Sports Medicine, Mental & Behavioral Health
  Email this study information to me
  Contact the study team

Site for Poly-omic predictors of symptom duration and recovery for adolescent concussion

Using micro-RNA in saliva coupled with survey data as a prognostic tool with the ability to guide clinical management of concussions
Brennen Harding at bharding@pennstatehealth.psu.edu or 717-531-5656
All
All
This study is NOT accepting healthy volunteers
NCT04582682
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
13-18 years old
Diagnosis of concussion
Exclusion Criteria:
more than 48 hours after injury
Neurology, Sports Medicine
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA